IDH1 and central nervous system cancer: Preclinical studies evaluated IDH inhibition together with immune checkpoint inhibition (ICI) to enhance efficacy of adoptive T-cell transfer of mice vaccinated with a IDH1-R132H peptide [7] or peptides derived from glioma-associated antigens [54].